464 related articles for article (PubMed ID: 33861431)
21. Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases.
Gelsi-Boyer V; Brecqueville M; Devillier R; Murati A; Mozziconacci MJ; Birnbaum D
J Hematol Oncol; 2012 Mar; 5():12. PubMed ID: 22436456
[TBL] [Abstract][Full Text] [Related]
22. Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.
Patnaik MM; Lasho TL
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):450-459. PubMed ID: 33275756
[TBL] [Abstract][Full Text] [Related]
23. Chronic Myelomonocytic Leukemia: Focus on Clinical Practice.
Patnaik MM; Tefferi A
Mayo Clin Proc; 2016 Feb; 91(2):259-72. PubMed ID: 26848006
[TBL] [Abstract][Full Text] [Related]
24. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations.
Meggendorfer M; Bacher U; Alpermann T; Haferlach C; Kern W; Gambacorti-Passerini C; Haferlach T; Schnittger S
Leukemia; 2013 Sep; 27(9):1852-60. PubMed ID: 23628959
[TBL] [Abstract][Full Text] [Related]
25. [Role of ASXL1 mutation in myeloid malignancies].
Sheng MY; Zhou Y; Xu MJ; Yang FC
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Aug; 22(4):1183-7. PubMed ID: 25130853
[TBL] [Abstract][Full Text] [Related]
26. Genomic Landscape and Risk Stratification in Chronic Myelomonocytic Leukemia.
Hunter A; Padron E
Curr Hematol Malig Rep; 2021 Jun; 16(3):247-255. PubMed ID: 33660195
[TBL] [Abstract][Full Text] [Related]
27. Epigenetic regulation by ASXL1 in myeloid malignancies.
Yang FC; Agosto-Peña J
Int J Hematol; 2023 Jun; 117(6):791-806. PubMed ID: 37062051
[TBL] [Abstract][Full Text] [Related]
28. Targeted deep sequencing improves outcome stratification in chronic myelomonocytic leukemia with low risk cytogenetic features.
Palomo L; Garcia O; Arnan M; Xicoy B; Fuster F; Cabezón M; Coll R; Ademà V; Grau J; Jiménez MJ; Pomares H; Marcé S; Mallo M; Millá F; Alonso E; Sureda A; Gallardo D; Feliu E; Ribera JM; Solé F; Zamora L
Oncotarget; 2016 Aug; 7(35):57021-57035. PubMed ID: 27486981
[TBL] [Abstract][Full Text] [Related]
29. [Research progress on genes associated with transformation of myelodysplastic syndromes to acute myeloid leukemia].
Zhu C; Ma Y; Xu XP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Jun; 22(3):873-8. PubMed ID: 24989313
[TBL] [Abstract][Full Text] [Related]
30. The Prognostic Ability of RAS Pathway-Related Gene Mutations in Patients with Myeloid Neoplasms Treated with Hypomethylating Agents.
Park HS; Son BR; Shin KS; Byeon S; Kim HK; Yang Y; Jeong Y; Han HS; Lee KH; Kwon J
Acta Haematol; 2021; 144(6):649-659. PubMed ID: 34233332
[TBL] [Abstract][Full Text] [Related]
31. Prognostic significance of SETBP1 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia, and chronic neutrophilic leukemia: A meta-analysis.
Shou LH; Cao D; Dong XH; Fang Q; Wu Y; Zhang Y; Fei JP; Xu BL
PLoS One; 2017; 12(2):e0171608. PubMed ID: 28158286
[TBL] [Abstract][Full Text] [Related]
32. Cohesin complex mutations in myeloid neoplasms are enriched for SRSF2, RUNX1, TET2, and NRAS co-mutations and morphologic dysplasia.
Hirt CK; Padmanabha N; Michaels PD
Leuk Res; 2023 Sep; 132():107357. PubMed ID: 37481994
[No Abstract] [Full Text] [Related]
33. CSF3R T618I, SETBP1 G870S, SRSF2 P95H, and ASXL1 Q780* tetramutation co-contribute to myeloblast transformation in a chronic neutrophilic leukemia.
Qian Y; Chen Y; Li X
Ann Hematol; 2021 Jun; 100(6):1459-1461. PubMed ID: 33822276
[TBL] [Abstract][Full Text] [Related]
34. Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.
Tsai SC; Shih LY; Liang ST; Huang YJ; Kuo MC; Huang CF; Shih YS; Lin TH; Chiu MC; Liang DC
Clin Cancer Res; 2015 Aug; 21(15):3541-51. PubMed ID: 25840971
[TBL] [Abstract][Full Text] [Related]
35. Chronic Myelomonocytic Leukemia: a Genetic and Clinical Update.
McCullough KB; Patnaik MM
Curr Hematol Malig Rep; 2015 Sep; 10(3):292-302. PubMed ID: 26122388
[TBL] [Abstract][Full Text] [Related]
36. Prognostic significance of ASXL1 mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia: A meta-analysis.
Lin Y; Zheng Y; Wang ZC; Wang SY
Hematology; 2016 Sep; 21(8):454-61. PubMed ID: 27077763
[TBL] [Abstract][Full Text] [Related]
37. Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A.
Jankowska AM; Makishima H; Tiu RV; Szpurka H; Huang Y; Traina F; Visconte V; Sugimoto Y; Prince C; O'Keefe C; Hsi ED; List A; Sekeres MA; Rao A; McDevitt MA; Maciejewski JP
Blood; 2011 Oct; 118(14):3932-41. PubMed ID: 21828135
[TBL] [Abstract][Full Text] [Related]
38. Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without absolute monocytosis) displays a similar clinicopathologic and mutational profile to classical chronic myelomonocytic leukemia.
Geyer JT; Tam W; Liu YC; Chen Z; Wang SA; Bueso-Ramos C; Oak J; Arber DA; Hsi E; Rogers HJ; Levinson K; Bagg A; Hassane DC; Hasserjian RP; Orazi A
Mod Pathol; 2017 Sep; 30(9):1213-1222. PubMed ID: 28548124
[TBL] [Abstract][Full Text] [Related]
39. ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia.
Gelsi-Boyer V; Trouplin V; Roquain J; Adélaïde J; Carbuccia N; Esterni B; Finetti P; Murati A; Arnoulet C; Zerazhi H; Fezoui H; Tadrist Z; Nezri M; Chaffanet M; Mozziconacci MJ; Vey N; Birnbaum D
Br J Haematol; 2010 Nov; 151(4):365-75. PubMed ID: 20880116
[TBL] [Abstract][Full Text] [Related]
40. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.
Tefferi A
Leukemia; 2010 Jun; 24(6):1128-38. PubMed ID: 20428194
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
